In-Vivo Science Inc. is a non-clinical research organization (CRO) that provides in vivo efficacy studies using humanized mice and other disease models. The company provides comprehensive support ranging from breeding animals to data analysis, assisting pharma sector from basic discovery to clinical application.
In-Vivo Science Inc. offers drug efficacy study in mice and rats. They have many models available in oncology, cardiovascular, and inflammatory disorders.
In cardiovascular models, they perform non-invasive cardiac function analyses using MRI. This enables precise and quantitative evaluation of therapeutic candidate compounds. By combining disease models with advanced imaging analysis technology, they ensure high accuracy and reliability throughout their service.
In-Vivo Science Inc. offers humanized mice models with immuno-deficient NOG mice. These mice, reconstituted with human immune cells, are used for preclinical assessment of immunotherapies and other advanced treatments.
The platform supports preclinical testing of immunotherapies such as PD-1 inhibitors and CAR-T cell therapies. Because human immune responses can be reproduced in vivo, these models allow drug efficacy to be verified under similar conditions as clinical patients.
In-Vivo Science Inc. provides many animal models suitable for diverse diseases. They offer end-to-end service throughout the whole processe—from animal housing and administration support through observation and data analysis. All studies are performed in-house, allowing seamless support from model selecting, study designing, in -life study to data delivery.
The company’s advantage is in their broad capability to handle various research areas, including oncology, cardiovascular diseases, and arthritis.
In-Vivo Science Inc. provides many advanced human disease models with NOG mice, which exhibit a high level of immuno-deficiency and are well-suited for transplanting human cells and tissues.
These models can reproduce human diseases such as cancer and immune disorders, allowing both efficacy and safety evaluations.
This model can also be applied to PDX (Patient-Derived Xenograft) study with patient-derived cells and tissues. It provides highly clinically relevant preclinical platform.
Reference: https://www.invivoscience.com/nog_mouse.html
This model—created by transplanting human hepatocytes into severely immuno-deficient TK-NOG mice—reconstructs a functional human liver.
Serum proteins( human albumin and human C3) are synthesized, and hepatic metabolic enzymes (e.g., CYP3A4) are expressed at donor-equivalent levels.
This enables high-precision evaluation of human drug metabolism, pharmacokinetics, and safety (toxicity).
Reference: https://www.invivoscience.com/tk-nog_mouse.html
| Address | 3F, No.44 Kowa Building, 1-2-7 Higashiyama, Meguro-ku, Tokyo, Japan |
|---|---|
| Tel | 044-201-8518 |
| Website | https://www.invivoscience.com/ |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.